MJFF has forged strategic partnerships to provide tools and resources for researchers, and to help people with PD. These tools include multiple MJFF sponsored PD rodent models available to the research community.
Parkinson's disease is a progressive movement disorder that results from degeneration of dopamine producing cells in the brain. More than 10 million people worldwide are living with this disorder, and the combined direct and indirect cost of Parkinson's including treatment, social security payments and lost income from inability to work, is estimated to be almost $25 billion per year in the United States alone. While it is recognized that there are both genetic and environmental contributors leading to the disease, the exact cause of PD is unknown. Intriguing new research even suggests that the gut microbiome may play a role in contributing to Parkinson's disease.
Recent research describes the presence of LRRK2 in immune cells and its relationship to Parkinson's disease. Additionally, MJFF provides further information about their MJFF LRRK2 research efforts.
A great example of the Michael J. Fox Foundation's commitment to providing access to important models via strategic partnerships is illustrated by their work with Taconic Biosciences to make LRRK2 models available to researchers.
Dr. Nicole Polinski, an Associate Director of the Preclinical Tools and Animal Models portfolios at MJFF commented, "Providing researchers with open access to pre-clinical models is an important investment for speeding research into the pathology and treatment of Parkinson's disease. This model (LRRK2 G2019S Mouse) in particular is novel and advantageous in that it is a targeted mutation with endogenous regulation and may therefore recapitulate the LRRK2 G2019S-related pathological mechanisms of this clinically-relevant mutation."